Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (NDUFB9) is an accessory subunit of mitochondrial complex I (NADH:ubiquinone oxidoreductase), the largest enzyme complex of the electron transport chain, embedded in the inner mitochondrial membrane. NDUFB9 is not directly involved in electron transfer catalysis but is necessary for structural integrity and function of complex I, facilitating the transfer of electrons from NADH to ubiquinone, which is key for ATP synthesis via oxidative phosphorylation. Mutations or reductions in NDUFB9 are linked to mitochondrial complex I deficiency, associated with a spectrum of disorders including neurological, muscular, and metabolic diseases as well as certain cancers. The gene product is a 22kDa protein of the LYRM family, characterized by a conserved LYR motif[1][2][3][4][10][12].
Inhibition of complex I disrupts electron flow and ATP production; drugs targeting complex I generally impair mitochondrial function[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (NDUFB9).